The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 22, 2014

Filed:

Dec. 18, 2009
Applicants:

Adam Cook, Boulder, CO (US);

Kevin W. Hunt, Boulder, CO (US);

Robert Kirk Delisle, Boulder, CO (US);

Todd Romoff, Bradenton, FL (US);

Christopher T. Clark, Boulder, CO (US);

Ganghyeok Kim, Boulder, CO (US);

Christopher P. Corrette, Boulder, CO (US);

George A. Doherty, Boulder, CO (US);

Laurence E. Burgess, Boulder, CO (US);

Inventors:

Adam Cook, Boulder, CO (US);

Kevin W. Hunt, Boulder, CO (US);

Robert Kirk Delisle, Boulder, CO (US);

Todd Romoff, Bradenton, FL (US);

Christopher T. Clark, Boulder, CO (US);

Ganghyeok Kim, Boulder, CO (US);

Christopher P. Corrette, Boulder, CO (US);

George A. Doherty, Boulder, CO (US);

Laurence E. Burgess, Boulder, CO (US);

Assignee:

Array BioPharma Inc., Boulder, CO (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 405/12 (2006.01); A61K 31/4433 (2006.01); C07D 241/20 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61P 11/06 (2006.01); A61P 27/14 (2006.01); A61P 17/00 (2006.01); A61P 29/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

Compounds of Formula I: (I) in which A, A, R, R, R, Rand Rhave the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D(PGD). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.


Find Patent Forward Citations

Loading…